Gefitinib vs Lazertinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Gefitinib
Marketed by AstraZeneca
NCT00020709 · Phase 3 · completed
SWOG S0023 registered 840 patients for chemoradiation and docetaxel consolidation; 243 of them were then randomized, double-blind, to gefitinib or placebo maintenance. The primary endpoint, overall survival, is a hard clinical outcome. An unplanned interim analysis stopped the randomized comparison, and survival was shorter with gefitinib than with placebo. The key result shown was recovered from the cited publication.
Next expected readout: July 2027 · NCT03333343 (registry estimate)
Reported efficacy
Overall Survival (From date of registration to date of death due to any cause, assessed up to 10 years); Progression-free survival (From date of registration to date of first observation of progressive disease, death due to any cause, assessed up to 10 years): Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 (missed)
Result source: NCT00020709
Lazertinib
Marketed by Johnson & Johnson and partners
NCT04248829 · Phase 3 · completed
The trial randomized 393 participants to lazertinib or an active gefitinib control with double-blind treatment. Its primary clinical endpoint, investigator-assessed progression-free survival, was met: median 20.6 vs 9.7 months (HR 0.45, 95% CI 0.34 to 0.58; P < .001; PMID 37379502).
Next expected readout: December 2026 · NCT05463224 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46) (met)
Result source: NCT04487080
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Gefitinib | Lazertinib |
|---|---|---|
| PFS, median | 5.4 vs 5.4±0 vs placeboNCT0154417914 other results
| 20.6 vs 9.7vs GefitnibNCT042488296 other results
|
| OS, median | 14.8 vs 17.2−2.4 vs placeboNCT015441798 other results
| 9.1bNCT040753961 other result
|
| ORR | 31.6% vs 34.1%−2.5 vs placeboNCT015441795 other results
| 76% vs 76.1%vs GefitnibNCT042488292 other results
|
| Duration of response, median | —Not posted · NCT03653546 | 19.4 vs 8.3vs GefitnibNCT042488291 other result
|
PFS, median
- Gefitinib
- 5.4 vs 5.4±0 vs placeboNCT01544179
14 other results
- 5.7 vs 5.8 NCT00322452
- 9.7 vs 4.2 NCT01404260
- 4.8 vs 2.6 NCT00770588
- 4.9 vs 4.4 NCT01982955
- 1.4 vs 4.3 NCT00264498
- 24.5 vs 9.9 NCT02039674
- 10.2 vs 4.3 NCT01982955
- 19.5 vs 22.0 NCT02856893
- 9.7 NCT01203917
- 7.0 NCT01203917
- 5.7 NCT00608868
- 3.4 NCT00824746
- 2.8 NCT01530334
- 5 NCT00328562
- Lazertinib
- 20.6 vs 9.7vs GefitnibNCT04248829
6 other results
- 23.7 vs 16.6 NCT04487080
- 18.5 vs 16.6 NCT04487080
- 8.3 vs 4.2 NCT04988295
- 6.3 vs 4.2 NCT04988295
- 3.1 NCT04075396
- 4.2 NCT04075396
OS, median
- Gefitinib
- 14.8 vs 17.2−2.4 vs placeboNCT01544179
8 other results
- 18.8 vs 17.4 NCT00322452
- 18.7 vs 16.9 NCT00770588
- 34.5 vs 21.1 NCT02039674
- 17.3 vs 19.5 NCT01982955
- 19.2 NCT01203917
- 10.2 NCT01530334
- 10 NCT00328562
- 23 vs 35 NCT00020709
- Lazertinib
- 9.1bNCT04075396
1 other result
- 7.7 NCT04075396
ORR
- Gefitinib
- 31.6% vs 34.1%−2.5 vs placeboNCT01544179
5 other results
- 55% vs 28.6% NCT02039674
- 29.5% NCT02039674
- 45.2% vs 33.3% NCT01982955
- 33.3% NCT01982955
- 33.3% NCT01982955
- Lazertinib
- 76% vs 76.1%vs GefitnibNCT04248829
2 other results
- 26.7% NCT04075396
- 7.7% NCT04075396
Duration of response, median
- Gefitinib
- —Not posted · NCT03653546
- Lazertinib
- 19.4 vs 8.3vs GefitnibNCT04248829
1 other result
- 2.8 NCT04075396
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. Gefitinib: 9 of 9 rows · Lazertinib: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Gefitinib Rows use multiple source trials | Lazertinib Rows use multiple source trials |
|---|---|---|
| Disease Control responder rate · % of participants | 84.2% (n=133) vs 78.8% (n=132) placeboa,b,c NCT01544179 · Phase 3 · registry result, not featured evidence 1 other source trial83.9% (n=31) vs 70.8% (n=24) Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination | 93.9% (n=196) vs 93.9% (n=197) Gefitnib240 mga,b,c NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 |
| Disease Control responder rate · % of participants No placebo or comparator arm | 58.3% (n=12)500 mg + 250 mgd,a,b,c NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination show 1 more dose50% (n=6)300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination | 60% (n=15)240 mgd,a,b,c NCT04075396 · Phase 1/2 · registry result, not featured evidence show 1 more dose53.8% (n=13)320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence |
| ORR responder rate · % of participants No placebo or comparator arm | 29.5% (n=44)a,b,c NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 2 other source trials33.3% (n=6)300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 33.3% (n=12)500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination | 26.7% (n=15)240 mgd,a,b,c NCT04075396 · Phase 1/2 · registry result, not featured evidence show 1 more dose7.7% (n=13)320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence |
| Overall Survival time to event · months No placebo or comparator arm | 19.22 monthse,a,b,c NCT01203917 · Phase 4 · registry result, not featured evidence 2 other source trials10.22 months* NCT01530334 · Phase 2 · registry result, not featured evidence · converted to months from 311 days as posted 10 months NCT00328562 · Phase 1 · registry result, not featured evidence · combination | 9.1 months240 mgd,e,a,b,c NCT04075396 · Phase 1/2 · registry result, not featured evidence show 1 more dose7.7 months320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence |
| PFS time to event · months No placebo or comparator arm | 9.72 monthsd,e,a,b,c NCT01203917 · Phase 4 · registry result, not featured evidence show 1 more dose6.97 months NCT01203917 · Phase 4 · registry result, not featured evidence | 3.1 months240 mgd,e,a,b,c NCT04075396 · Phase 1/2 · registry result, not featured evidence show 1 more dose4.2 months320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence |
| Dropout rate | 40.6%f NCT00322452 · Phase 3 show 40 more results—250 mg NCT01203917 · Phase 4 · registry result, not featured evidence 33.6%Gefitinib NCT01203917 · Phase 4 · registry result, not featured evidence 54.7%250 mg NCT00770588 · Phase 4 · registry result, not featured evidence 9.6% NCT00608868 · Phase 4 · registry result, not featured evidence —250 mg NCT01544179 · Phase 3 · registry result, not featured evidence 47.4%Gefitinib NCT01544179 · Phase 3 · registry result, not featured evidence 0.8% NCT00049543 · Phase 3 · registry result, not featured evidence 62.3% NCT02856893 · Phase 2 · registry result, not featured evidence —800 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —600 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —100 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 83.6% NCT01530334 · Phase 2 · registry result, not featured evidence 0% NCT00824746 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT00264498 · Phase 2 · registry result, not featured evidence —200 mg NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestonePart 2 Cohort G+ (Pembro 200 mg+Pe NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort B10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort C10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort D1 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort D2 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination —Part 1 Cohort A2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort B2 (Pembro 2mg/kg+Pa NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort C2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort D4 (Pembro 2 mg/kg+I NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort E (Pembro 2 mg/kg+Er NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 1 Cohort F (Pembro 2 mg/kg+Ge NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestonePart 2 Cohort H (Pembro 2mg/kg+I) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination —Part 1 Cohort A10 (Pembro10mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 0%500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 0%300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 7.7% NCT00328562 · Phase 1 · registry result, not featured evidence · combination | 44.9%240 mgg NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more results78.1%Experimental: Arm A (Open-label): NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 75%Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 74.5%Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 80.2%Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —240 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —f NCT00322452 · Phase 3 show 40 more results—250 mg NCT01203917 · Phase 4 · registry result, not featured evidence —Gefitinib NCT01203917 · Phase 4 · registry result, not featured evidence 6.1%250 mg NCT00770588 · Phase 4 · registry result, not featured evidence 0.6% NCT00608868 · Phase 4 · registry result, not featured evidence —250 mg NCT01544179 · Phase 3 · registry result, not featured evidence 0%Gefitinib NCT01544179 · Phase 3 · registry result, not featured evidence — NCT00049543 · Phase 3 · registry result, not featured evidence 3.8% NCT02856893 · Phase 2 · registry result, not featured evidence —800 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —600 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination —200 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination —100 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 4.9% NCT01530334 · Phase 2 · registry result, not featured evidence — NCT00824746 · Phase 2 · registry result, not featured evidence — NCT00264498 · Phase 2 · registry result, not featured evidence —200 mg NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy 3.3%Part 2 Cohort G+ (Pembro 200 mg+Pe NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 7.7%Part 1 Cohort B10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort C10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort D1 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort D2 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination —Part 1 Cohort A2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort B2 (Pembro 2mg/kg+Pa NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort C2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 16.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 8.3%Part 1 Cohort E (Pembro 2 mg/kg+Er NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 1 Cohort F (Pembro 2 mg/kg+Ge NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 3%Part 2 Cohort H (Pembro 2mg/kg+I) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination —Part 1 Cohort A10 (Pembro10mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination —500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination —500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination —300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination — NCT00328562 · Phase 1 · registry result, not featured evidence · combination | 9.7%240 mgg NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more results—Experimental: Arm A (Open-label): NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —240 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence —320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 18.1%f NCT00322452 · Phase 3 show 40 more results19.6%250 mg NCT01203917 · Phase 4 · registry result, not featured evidence —Gefitinib NCT01203917 · Phase 4 · registry result, not featured evidence 6.8%250 mg NCT00770588 · Phase 4 · registry result, not featured evidence 16.2% NCT00608868 · Phase 4 · registry result, not featured evidence 28.8%250 mg NCT01544179 · Phase 3 · registry result, not featured evidence —Gefitinib NCT01544179 · Phase 3 · registry result, not featured evidence 13.7% NCT00049543 · Phase 3 · registry result, not featured evidence 17% NCT02856893 · Phase 2 · registry result, not featured evidence 42.9%800 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 60%600 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 22.6%400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 33.3%400 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 33.3%400 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 40.4%400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 37.5%400 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 0%200 mg Cap BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 28.6%200 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 71.4%200 mg Tab BID NCT01610336 · Phase 2 · registry result, not featured evidence · combination 20%100 mg Cap QD NCT01610336 · Phase 2 · registry result, not featured evidence · combination 17.2% NCT01530334 · Phase 2 · registry result, not featured evidence — NCT00824746 · Phase 2 · registry result, not featured evidence — NCT00264498 · Phase 2 · registry result, not featured evidence 25%200 mg NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy 50.8%Part 2 Cohort G+ (Pembro 200 mg+Pe NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 61.5%Part 1 Cohort B10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 58.3%Part 1 Cohort C10 (Pembro 10 mg/kg NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 1 Cohort D1 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 1 Cohort D2 (Pembro 10 mg/kg+ NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 53.8%Part 1 Cohort A2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 72.7%Part 1 Cohort B2 (Pembro 2mg/kg+Pa NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 50%Part 1 Cohort C2 (Pembro 2 mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 41.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 66.7%Part 1 Cohort E (Pembro 2 mg/kg+Er NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 71.4%Part 1 Cohort F (Pembro 2 mg/kg+Ge NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 36.4%Part 2 Cohort H (Pembro 2mg/kg+I) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 41.7%Part 1 Cohort A10 (Pembro10mg/kg+P NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 58.3%500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 41.9%500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 66.7%300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 41.7% NCT00328562 · Phase 1 · registry result, not featured evidence · combination | 26%240 mgg NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more results48.7%Experimental: Arm A (Open-label): NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 35.2%Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 52.1%Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 32.3%Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 66.7%240 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence 46.2%320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | show 37 more results250 mg rash 46.7% diarrhoea 29% asthenia 11.2% NCT01203917 · Phase 4 · registry result, not featured evidence 250 mg rash 49.7% (placebo 9.5%) serious hepatic dysfunction 29.3% (placebo 10.8%) diarrhoea 25.2% (placebo 8.8%) NCT00770588 · Phase 4 · registry result, not featured evidence 250 mg nausea 63.6% (placebo 60.6%) decreased appetite 48.5% (placebo 34.1%) vomiting 40.9% (placebo 32.6%) NCT01544179 · Phase 3 · registry result, not featured evidence rash 67.1% (placebo 27.2%) diarrhea 62.2% (placebo 30.9%) fatigue 54.2% (placebo 53.5%) NCT00049543 · Phase 3 · registry result, not featured evidence diarrhea 50.9% dry skin 41.5% weight loss 35.8% NCT02856893 · Phase 2 · registry result, not featured evidence 800 mg Cap QD vomiting 100% nausea 85.7% decreased appetite 57.1% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 600 mg Cap BID cough 60% decreased appetite 60% hypoproteinaemia 40% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 400 mg Cap BID hypoalbuminaemia 43.4% anaemia 34% oedema peripheral 28.3% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 400 mg Cap BID hypoalbuminaemia 58.3% blood bilirubin increased 41.7% amylase increased 33.3% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 400 mg Cap QD nausea 50% cough 33.3% oedema peripheral 33.3% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 400 mg Tab BID nausea 55.3% oedema peripheral 44.7% decreased appetite 40.4% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 400 mg Tab BID decreased appetite 37.5% diarrhoea 37.5% headache 37.5% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 200 mg Cap BID diarrhoea 75% hypoalbuminaemia 75% anaemia 50% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 200 mg Cap QD back pain 57.1% rash 42.9% vomiting 42.9% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 200 mg Tab BID nausea 71.4% dermatitis acneiform 57.1% cystitis 42.9% NCT01610336 · Phase 2 · registry result, not featured evidence · combination 100 mg Cap QD constipation 60% pruritus 60% amylase increased 40% NCT01610336 · Phase 2 · registry result, not featured evidence · combination diarrohea 27.6% rash 15.5% vomiting 15.5% NCT01530334 · Phase 2 · registry result, not featured evidence diarrhoea 53.8% dyspnoea 34.6% nausea 30.8% NCT00264498 · Phase 2 · registry result, not featured evidence 200 mg decreased appetite 32.1% (placebo 27.4%) fatigue 25% (placebo 58.1%) cough 21.4% (placebo 27.4%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy nausea 72.9% (placebo 59.7%) fatigue 69.5% (placebo 58.1%) constipation 54.2% (placebo 40.3%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination alopecia 61.5% (placebo 3.2%) cough 53.8% (placebo 27.4%) decreased appetite 53.8% (placebo 27.4%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination fatigue 91.7% (placebo 58.1%) constipation 58.3% (placebo 40.3%) anaemia 50% (placebo 58.1%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination fatigue 100% (placebo 58.1%) actinic keratosis 33.3% (placebo 1.6%) back pain 33.3% (placebo 12.9%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination arthralgia 66.7% (placebo 29%) chills 66.7% (placebo 4.8%) cough 66.7% (placebo 27.4%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination constipation 61.5% (placebo 40.3%) fatigue 61.5% (placebo 58.1%) alopecia 53.8% (placebo 3.2%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination constipation 81.8% (placebo 40.3%) alopecia 72.7% (placebo 3.2%) fatigue 72.7% (placebo 58.1%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination constipation 66.7% (placebo 40.3%) nausea 58.3% (placebo 59.7%) fatigue 50% (placebo 58.1%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination constipation 41.7% (placebo 40.3%) vomiting 41.7% (placebo 32.3%) cough 33.3% (placebo 27.4%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 66.7% (placebo 30.6%) fatigue 58.3% (placebo 58.1%) cough 50% (placebo 27.4%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 57.1% (placebo 30.6%) pruritus 42.9% (placebo 11.3%) rash 28.6% (placebo 16.1%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination fatigue 48.5% (placebo 58.1%) constipation 27.3% (placebo 40.3%) arthralgia 24.2% (placebo 29%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination fatigue 66.7% (placebo 58.1%) alopecia 58.3% (placebo 3.2%) constipation 58.3% (placebo 40.3%) NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination 500 mg + 250 mg diarrhoea 83.3% dyspnoea exertional 41.7% fatigue 41.7% NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 500 mg + 250 mg diarrhoea 58.1% oedema peripheral 38.7% amylase increased 35.5% NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 300 mg + 250 mg amylase increased 66.7% diarrhoea 66.7% blood alkaline phosphatase increased 50% NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination diarrhea 41.7% dysphagia 33.3% rash 33.3% NCT00328562 · Phase 1 · registry result, not featured evidence · combination | 240 mgg paraesthesia 39.3% rash 36.2% pruritus 26.5% NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more resultsparonychia 68.4% infusion related reaction 62% rash 61.8% NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 rash 44.6% diarrhoea 31.9% paronychia 28.6% NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 neutropenia 65.8% thrombocytopenia 59.3% infusion related reaction 54% NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 infusion related reaction 56.9% neutropenia 56.2% nausea 44.6% NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 240 mg anaemia 46.7% diarrhoea 46.7% aspartate aminotransferase increased 26.7% NCT04075396 · Phase 1/2 · registry result, not featured evidence 320 mg nausea 61.5% diarrhoea 53.8% arthralgia 23.1% NCT04075396 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 4 versus Phase 1/2.
- fPopulation comparability has not been reviewed for these studies.
- gPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Gefitinib
show 6 more results
show 1 more result
show 1 more result
show 1 more result
+ 10 further endpoints in the CSV export.
Lazertinib
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gefitinib's landscape · Lazertinib's landscape